Know Cancer

forgot password

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Phase 1
18 Years
Not Enrolling
Glioblastoma, Malignant Gliomas

Thank you

Trial Information

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Inclusion Criteria:

- Patients with glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma
(AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO),
malignant glioma/astrocytoma NOS (not otherwise specified). Also included will be
radiographically diagnosed infiltrating brain stem gliomas not amenable to biopsy.
Other CNS tumor histologies will not be eligible for this trial.

- Patients must have shown either evidence for tumor recurrence or progression by CT or
(preferably) MRI scan performed within 21 days prior to registration or had biopsy
proven recurrent glioma within the last 12 weeks prior to enrollment (in order to
allow the enrollment of patients with recurrent gliomas who have undergone a complete
radiographic resection and now have no radiographic evaluable disease)

- Patients having undergone recent resection of a recurrent or progressive tumor will
be eligible two weeks after surgery.

- Patient must have failed prior radiation therapy and must have an interval of greater
than or equal to 2 weeks from the completion of radiation therapy to study entry.

- All patients must sign an informed consent, or if cognitively impaired, their
assigned DPA, indicating that they are aware of the investigational nature of this

- Patients must be > 18 years old, and must have a life expectancy > 8 weeks.

- Patients must have a Karnofsky performance status of > 60.

- Additionally, patients must be at least 6 weeks from nitrosoureas, 4 weeks from
temozolomide or carboplatin, 3 weeks from procarbazine, and 2 weeks from last
vincristine administration. Patients must be at least 4 weeks from other cytotoxic
therapies not listed above and 2 weeks for non-cytotoxic agents (e.g., interferon,

- Patients must have adequate bone marrow function (granulocyte count >= 1500/mm3,
platelet count of > 100,000/mm3, and hemoglobin > 8 gm%), adequate liver function
(total bilirubin <= 1.5 mg/dL, AST/ALT <= 2 x ULN), and adequate renal function
(creatinine <= 1.5 mg/dL or creatinine clearance > 60 cc/min) before starting
therapy. These tests must be performed within 14 days prior to registration.
Eligibility level for hemoglobin may be reached by transfusion. Eligibility level
for platelets may not be reached by transfusion.

- Patients must either not be receiving steroids, or be on a stable dose of steroids
for at least five days prior to registration.

- Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix) are ineligible, unless they are in complete
remission and off all therapy for that disease for a minimum of 3 years.

- Patients must not be pregnant or nursing, and all patients (both men and women) must
be willing to practice birth control during and for 2 months after treatment with
CC-8490. Women of childbearing potential (WCBP) who are sexually active must agree to
use adequate contraceptive methods (oral, injectable, or implantable hormonal
contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with
spermicide; or vasectomized partner).

- Patients must be able to swallow capsules whole.

Exclusion Criteria:

- Patients who, in the view of the treating physician, have significant active cardiac,
hepatic, renal, or psychiatric diseases that would significantly increase the risk of
using CC-8490 are ineligible.

- Concurrent use of other standard chemotherapeutics or investigative agents.

- Pregnant or lactating females.

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study, obscures the
evaluation of toxicity or alters drug metabolism.

- Use of other experimental study drug within 28 days of registration.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

December 2003

Completion Date:

June 2005

Related Keywords:

  • Glioblastoma
  • Malignant Gliomas
  • CC-8490
  • CC8490
  • Glio
  • Glioblastoma
  • Malignant Gliomas
  • Glioblastoma
  • Glioma



Neuro Oncology BranchNational Cancer Institute Bethesda, Maryland  20892-8200